Abstract
Background The extracellular microenvironment modulates cancer behavior. Although radiographic contrast enhancement is an ominous finding in gliomas, it remains unclear if the associated blood-brain barrier disruption merely reflects or functionally supports tumor aggressiveness.
Methods We utilized intra-operative microdialysis to sample the extracellular metabolome of radiographically diverse regions during fifteen neurosurgical resections. The global extracellular metabolome of recovered microdialysate was evaluated via ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) and assessed using enrichment and correlation analyses.
Results Among 162 named metabolites identified via ultra-performance liquid chromatography tandem mass spectrometry, guanidinoacetate (GAA), was 126.32x higher in enhancing tumor than in adjacent brain. 48 additional metabolites were 2.05-10.18x more abundant in enhancing tumor than brain. With exception of GAA, and 2-HG in IDH-mutant gliomas, differences between non-enhancing tumor and brain microdialysate were comparatively modest and less consistent. The enhancing but not the non-enhancing glioma metabolome was significantly enriched for plasma-associated metabolites largely comprising amino acids and carnitines.
Conclusions Our findings suggest that metabolite diffusion through a disrupted blood-brain barrier may largely define the enhancing extracellular glioma metabolome. Future studies are needed to determine how the altered extracellular metabolome impacts glioma behavior.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04047264
Funding Statement
National Institute of Health: T32GM065841 to CRC, TCB was supported by NINDS NRCDP K12, NINDS R61 NS122096, Mayo Clinic Center for Individualized Medicine and CCaTS award UL1TR002377, the American Brain Tumor Association, Brains Together for the Cure, Humor to fight the Tumor, and Lucius & Terrie McKelvey. Support was also provided through NCI U54 CA210180 (JS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was conducted under IRB#19-004694 at the Mayo Clinic, Rochester, MN.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Ethics approval and consent to participate: This study was approved by the Mayo Clinic Institutional Review Board and all participants provided their consent to participate in this study.
Consent for publication: All participants have provided consent for publication.
Data availability statement: All data from this study are provided as a supplementary data file.
Funding: National Institute of Health: T32GM065841 to CRC, TCB was supported by NINDS NRCDP K12, NINDS R61 NS122096, Mayo Clinic Center for Individualized Medicine and CCaTS award UL1TR002377, the American Brain Tumor Association, Brains Together for the Cure, Humor to fight the Tumor, and Lucius & Terrie McKelvey. Support was also provided through NCI U54 CA210180 (JS).
Conflict of Interest: None.
Authorship: Study design and conception: TCB, CRC, LPC, KR, WFE
Performed experiments: TCB, CRC, LPC, KR, KJM, JJW, DAB
Analyzed data: TCB, CRC, KR
Critically reviewed manuscript: all authors
Upon continued analysis of data, we identified that the enhancing, blood-brain barrier disrupted portions of high-grade gliomas were enriched for plasma-associated metabolites compared to the non-enhancing tumor. We have revised the manuscript with these new analyses (Figure 5) along with the discussion of these results.
Data Availability
The data we have collected will be made publicly available upon later submission.
List of Abbreviations
- 2-HG
- 2-hydroxyglutarate
- 2-PY
- N1-methyl-2-pyridone-5-carboxamide
- B
- brain
- BBB
- Blood-brain barrier
- CNS
- central nervous system
- CSF
- cerebrospinal fluid
- CT
- computed tomography
- DFMO
- difluoromethylornithine
- E
- enhancing tumor
- FC
- fold-change
- FDR
- false-discovery rate
- GAA
- guanidinoacetate
- GBM
- glioblastoma
- GSEA
- gene set enrichment analysis
- HGG
- high-grade glioma
- HMW
- high molecular weight
- IDH
- isocitrate dehydrogenase
- IND
- investigational new drug
- LC/MS
- liquid chromatography-mass spectrometry
- NAA
- N-acetylaspartate
- NE
- non-enhancing tumor
- ODC
- ornithine decarboxylase
- WT
- wild type
- UPLC-MS/MS
- Ultra-performance liquid chromatography tandem mass spectrometry
